ABSTRACT This study establishes a green analytical method for the simultaneous quantification of five selected kinase inhibitor anticancer drugs (selumetinib, binimetinib, capmatinib, baricitinib, and brigatinib) and their effective eco‐friendly inactivation strategy. Chromatographic separation of the drugs and their degradation products were performed using a high‐performance liquid chromatography (HPLC) system and validated thereafter. It was performed on a C18 column (250 × 4.6 mm, 5 µm) using a gradient of 10 mM ammonium formate (pH 3.45) and acetonitrile at a flow rate of 1 mL/min, with %B programmed as 20/1, 31/3, 50/10, 50/11, 20/12, and 20/16 min. Inactivation efficiency of sodium hypochlorite, sodium hydroxide, and hydrogen peroxide was compared. Residual drug concentrations after treatment were quantified using the established analytical method. The gradient mode of analysis provided a good peak shape and optimum resolution between the analytes. The method was accurate, robust, and precise over a 0.15–150 µg/mL concentration range. Sodium hypochlorite (1%) achieved complete inactivation of all five kinase inhibitors within 1 h. Greenness assessments of the methods were performed using Modified Green Analytical Procedure Index, Analytical GREEnness, and Analytical Eco‐scale, scoring 78, 0.63, and 74, respectively. White analytical chemistry analysis through the Red Green Blue 12 model and Blue Applicability Grade Index software tool yielded a whiteness score of 95.8 and 77.5, confirming moderate to minimal environmental impact of the method. This is the first report introducing a chemical inactivation strategy for these kinase inhibitors, providing a practical solution for treating pharmaceutical and laboratory waste as well as expired products. This validated HPLC method is well‐suited for routine quality control analysis and monitoring of pharmaceutical effluents containing these kinase inhibitors. It supports enhanced environmental safety in healthcare and research laboratories while effectively addressing regulatory requirements for effluent treatment and disposal of such pharmaceutical compounds.
Borale et al. (2026) studied this question.